spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  melphalan 

 HSMN NewsFeed - 15 Mar 2024
Delcath Systems Announces $7 Million Private Placement
Biopharmaceuticals Drug Delivery Oncology Venture Capital
 HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Dec 2015
Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional Radiology
Devices Drug Delivery Interventional Oncology Radiology
 HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2015
CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Aug 2015
Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 24 Aug 2015
Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition
Biopharmaceuticals Devices Mergers & Acquisitions
 HSMN NewsFeed - 4 Mar 2015
CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2013
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Jul 2012
Delcath Announced Changes To Board Of Directors
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 18 Jun 2012
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
Devices Drug Delivery Oncology
 HSMN NewsFeed - 10 Apr 2012
Delcath Announces Agreement With Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital for Training and Launch of Hepatic Chemosat Delivery System
Devices Drug Delivery Oncology
 HSMN NewsFeed - 5 Apr 2012
Delcath Receives European Regulatory Approval for Second Generation Hemofiltration Cartridge
Devices Regulatory
 HSMN NewsFeed - 26 Mar 2012
Delcath Expands Global Marketing Team With Key Pharma Oncology Hire
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 19 Mar 2012
Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
Devices Drug Delivery Oncology
 HSMN NewsFeed - 9 Mar 2012
Delcath Selects Quintiles to Support EU Launch of CHEMOSAT
Devices Drug Delivery Oncology
 HSMN NewsFeed - 27 Feb 2012
Delcath Announces First CHEMOSAT Procedures in Germany
Devices Drug Delivery Oncology
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Apr 2011
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT Delivery System
Devices Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 22 Feb 2011
Delcath Systems Receives Refusal to File Letter From FDA
Devices Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 26 Jan 2011
Ligand Acquires CyDex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Dec 2010
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 6 Dec 2010
Delcath Submits CE Mark Technical File for Hepatic ChemoSAT Delivery System
Devices Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2009
Delcath Systems Reports Substantial Progress
Devices Oncology
 HSMN NewsFeed - 23 Oct 2009
Delcath Systems Completes Executive Management Team with Strategic New Hires
Devices Personnel
 HSMN NewsFeed - 2 Oct 2009
Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
Devices Oncology Personnel
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Sep 2009
Delcath Systems, Inc. Appoints David McDonald Chief Financial Officer
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2009
Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 2 Jun 2009
Delcath Systems Granted Third Orphan Drug Designation
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 18 Nov 2008
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2008
Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Apr 2008
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2008
Adherex Receives Orphan Drug Designation for ADH-1 in Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2007
Delcath Resumes Enrollment in Phase III and Phase II Trials
Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 23 Oct 2007
Delcath Voluntarily Defers Accrual in Clinical Trials
Devices Drug Delivery FDA
 HSMN NewsFeed - 4 Oct 2007
Delcath Systems Issues CEO Letter to Shareholders
Devices Drug Delivery Oncology
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2007
Delcath Systems, Inc. Moves Headquarters to New York
Devices
 HSMN NewsFeed - 20 Aug 2007
Samuel Herschkowitz, M.D. Resigns as Director of Delcath
Devices Personnel
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 May 2007
Delcath Systems Receives National Cancer Institute Approval to Expand Phase III Trial to Multiple Centers
Devices Drug Delivery Oncology
 HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Feb 2007
Delcath Elects Dr. Harold Koplewicz Chairman of the Board of Directors
Devices Personnel
 HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2006
Delcath Announces Resignation of M. S. Koly as CEO and Appointment of Richard Taney as Interim CEO
Devices Drug Delivery Personnel
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 39

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 39 additional stories matching:
melphalan
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.